The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.

JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Felmetatug vedotin’s exit could be bad news for Mersana.